Clinical · Comorbidities
HRT and Gallstones
Transdermal reduces gallstone risk vs oral estrogen.
Transdermal reduces gallstone risk vs oral estrogen. Kindr Health clinicians coordinate care with your existing specialists.
Decision framework
Individual risk-benefit, route of administration matters (transdermal bypasses hepatic first-pass), and current guidelines from NAMS, ACOG, and disease-specific societies.
What we do differently
We don't reflexively deny HRT for common comorbidities. Guidelines have evolved — many older 'contraindications' are now nuanced case-by-case decisions.
Frequently asked questions
Will my specialist agree?
We coordinate directly with your care team when helpful; most modern specialists follow current guidelines.
Is transdermal really safer?
For most vascular and metabolic conditions, yes — it bypasses liver first-pass.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.